A splashy syndicate, some big name partnerships and a technology designed to deliver a therapeutic payload more precisely have enticed public investors to Bicycle Therapeutics’ Nasdaq debut, which totaled at $61 million.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,